{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T06:02:22Z","timestamp":1768024942116,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12885-016-2305-2","type":"journal-article","created":{"date-parts":[[2016,4,14]],"date-time":"2016-04-14T10:52:53Z","timestamp":1460631173000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6\u2013producing lung carcinoma cells"],"prefix":"10.1186","volume":"16","author":[{"given":"Mariko","family":"Noguchi-Sasaki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Shimonaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Fujimoto-Ouchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,4,11]]},"reference":[{"issue":"3","key":"2305_CR1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nm.3814","volume":"21","author":"VG Sankaran","year":"2015","unstructured":"Sankaran VG, Weiss MJ. Anemia: progress in molecular mechanisms and therapies. Nat Med. 2015;21(3):221\u201330. doi: 10.1038\/nm.3814 .","journal-title":"Nat Med"},{"issue":"1","key":"2305_CR2","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s12032-007-9000-8","volume":"25","author":"HZ Grotto","year":"2008","unstructured":"Grotto HZ. Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol. 2008;25(1):12\u201321. doi: 10.1007\/s12032-007-9000-8 .","journal-title":"Med Oncol"},{"issue":"15","key":"2305_CR3","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2004.06.019","volume":"40","author":"H Ludwig","year":"2004","unstructured":"Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004;40(15):2293\u2013306. doi: 10.1016\/j.ejca.2004.06.019 .","journal-title":"Eur J Cancer"},{"issue":"2","key":"2305_CR4","doi-asserted-by":"crossref","first-page":"G199","DOI":"10.1152\/ajpgi.00412.2005","volume":"290","author":"T Ganz","year":"2006","unstructured":"Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am J Physiol Gastrointest Liver Physiol. 2006;290(2):G199\u2013203. doi: 10.1152\/ajpgi.00412.2005 .","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"2305_CR5","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1152\/physrev.00008.2013","volume":"93","author":"T Ganz","year":"2013","unstructured":"Ganz T. Systemic iron homeostasis. Physiol Rev. 2013;93(4):1721\u201341. doi: 10.1152\/physrev.00008.2013 .","journal-title":"Physiol Rev"},{"key":"2305_CR6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev.nutr.26.061505.111303","volume":"26","author":"E Nemeth","year":"2006","unstructured":"Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr. 2006;26:323\u201342. doi: 10.1146\/annurev.nutr.26.061505.111303 .","journal-title":"Annu Rev Nutr"},{"issue":"9","key":"2305_CR7","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/cncr.22999","volume":"110","author":"DS Hong","year":"2007","unstructured":"Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer. 2007;110(9):1911\u201328. doi: 10.1002\/cncr.22999 .","journal-title":"Cancer"},{"issue":"1","key":"2305_CR8","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2005-01-0160","volume":"106","author":"A Maccio","year":"2005","unstructured":"Maccio A, Madeddu C, Massa D, Mudu MC, Lusso MR, Gramignano G, et al. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. Blood. 2005;106(1):362\u20137. doi: 10.1182\/blood-2005-01-0160 .","journal-title":"Blood"},{"issue":"3","key":"2305_CR9","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.V86.3.900.900","volume":"86","author":"J Nieken","year":"1995","unstructured":"Nieken J, Mulder NH, Buter J, Vellenga E, Limburg PC, Piers DA, et al. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients. Blood. 1995;86(3):900\u20135.","journal-title":"Blood"},{"issue":"9","key":"2305_CR10","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1182\/blood-2006-06-027631","volume":"108","author":"DM Wrighting","year":"2006","unstructured":"Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood. 2006;108(9):3204\u20139. doi: 10.1182\/blood-2006-06-027631 .","journal-title":"Blood"},{"issue":"12","key":"2305_CR11","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2007-08-106195","volume":"111","author":"JP Pinto","year":"2008","unstructured":"Pinto JP, Ribeiro S, Pontes H, Thowfeequ S, Tosh D, Carvalho F, et al. Erythropoietin mediates hepcidin expression in hepatocytes through EPOR signaling and regulation of C\/EBPalpha. Blood. 2008;111(12):5727\u201333. doi: 10.1182\/blood-2007-08-106195 .","journal-title":"Blood"},{"issue":"5","key":"2305_CR12","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.peptides.2007.01.016","volume":"28","author":"E Fein","year":"2007","unstructured":"Fein E, Merle U, Ehehalt R, Herrmann T, Kulaksiz H. Regulation of hepcidin in HepG2 and RINm5F cells. Peptides. 2007;28(5):951\u20137. doi: 10.1016\/j.peptides.2007.01.016 .","journal-title":"Peptides"},{"issue":"4","key":"2305_CR13","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2004-08-3375","volume":"105","author":"S Rivera","year":"2005","unstructured":"Rivera S, Liu L, Nemeth E, Gabayan V, Sorensen OE, Ganz T. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood. 2005;105(4):1797\u2013802. doi: 10.1182\/blood-2004-08-3375 .","journal-title":"Blood"},{"issue":"9","key":"2305_CR14","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1172\/JCI200420945","volume":"113","author":"E Nemeth","year":"2004","unstructured":"Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271\u20136. doi: 10.1172\/jci20945 .","journal-title":"J Clin Invest"},{"issue":"6","key":"2305_CR15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3324\/haematol.10794","volume":"92","author":"H Kawabata","year":"2007","unstructured":"Kawabata H, Tomosugi N, Kanda J, Tanaka Y, Yoshizaki K, Uchiyama T. Anti-interleukin 6 receptor antibody tocilizumab reduces the level of serum hepcidin in patients with multicentric Castleman\u2019s disease. Haematologica. 2007;92(6):857\u20138.","journal-title":"Haematologica"},{"issue":"18","key":"2305_CR16","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1182\/blood-2010-03-271791","volume":"116","author":"SN Song","year":"2010","unstructured":"Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood. 2010;116(18):3627\u201334. doi: 10.1182\/blood-2010-03-271791 .","journal-title":"Blood"},{"issue":"1","key":"2305_CR17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2220\/biomedres.30.47","volume":"30","author":"K Mori","year":"2009","unstructured":"Mori K, Fujimoto-Ouchi K, Onuma E, Noguchi M, Shimonaka Y, Yasuno H, et al. Novel models of cancer-related anemia in mice inoculated with IL-6-producing tumor cells. Biomed Res. 2009;30(1):47\u201351.","journal-title":"Biomed Res"},{"issue":"3","key":"2305_CR18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/ijc.21038","volume":"116","author":"E Onuma","year":"2005","unstructured":"Onuma E, Tsunenari T, Saito H, Sato K, Yamada-Okabe H, Ogata E. Parathyroid hormone-related protein (PTHrP) as a causative factor of cancer-associated wasting: possible involvement of PTHrP in the repression of locomotor activity in rats bearing human tumor xenografts. Int J Cancer. 2005;116(3):471\u20138. doi: 10.1002\/ijc.21038 .","journal-title":"Int J Cancer"},{"issue":"3","key":"2305_CR19","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0165-2478(02)00202-X","volume":"84","author":"M Okazaki","year":"2002","unstructured":"Okazaki M, Yamada Y, Nishimoto N, Yoshizaki K, Mihara M. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett. 2002;84(3):231\u201340.","journal-title":"Immunol Lett"},{"issue":"24","key":"2305_CR20","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1002\/rcm.3319","volume":"21","author":"N Murao","year":"2007","unstructured":"Murao N, Ishigai M, Yasuno H, Shimonaka Y, Aso Y. Simple and sensitive quantification of bioactive peptides in biological matrices using liquid chromatography\/selected reaction monitoring mass spectrometry coupled with trichloroacetic acid clean-up. Rapid Commun Mass Spectrom. 2007;21(24):4033\u20138. doi: 10.1002\/rcm.3319 .","journal-title":"Rapid Commun Mass Spectrom"},{"issue":"6","key":"2305_CR21","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12185-012-1217-4","volume":"96","author":"Y Sasaki","year":"2012","unstructured":"Sasaki Y, Noguchi-Sasaki M, Yasuno H, Yorozu K, Shimonaka Y. Erythropoietin stimulation decreases hepcidin expression through hematopoietic activity on bone marrow cells in mice. Int J Hematol. 2012;96(6):692\u2013700. doi: 10.1007\/s12185-012-1217-4 .","journal-title":"Int J Hematol"},{"issue":"6","key":"2305_CR22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3324\/haematol.2012.075515","volume":"98","author":"L Falco De","year":"2013","unstructured":"De Falco L, Sanchez M, Silvestri L, Kannengiesser C, Muckenthaler MU, Iolascon A, et al. Iron refractory iron deficiency anemia. Haematologica. 2013;98(6):845\u201353. doi: 10.3324\/haematol.2012.075515 .","journal-title":"Haematologica"},{"issue":"2","key":"2305_CR23","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.bbrc.2003.12.096","volume":"314","author":"K Hagihara","year":"2004","unstructured":"Hagihara K, Nishikawa T, Isobe T, Song J, Sugamata Y, Yoshizaki K. IL-6 plays a critical role in the synergistic induction of human serum amyloid A (SAA) gene when stimulated with proinflammatory cytokines as analyzed with an SAA isoform real-time quantitative RT-PCR assay system. Biochem Biophys Res Commun. 2004;314(2):363\u20139.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"2305_CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","volume":"5","author":"CJ Schofield","year":"2004","unstructured":"Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004;5(5):343\u201354. doi: 10.1038\/nrm1366 .","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"2","key":"2305_CR25","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1006\/clim.1999.4736","volume":"92","author":"PV Voulgari","year":"1999","unstructured":"Voulgari PV, Kolios G, Papadopoulos GK, Katsaraki A, Seferiadis K, Drosos AA. Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin Immunol. 1999;92(2):153\u201360. doi: 10.1006\/clim.1999.4736 .","journal-title":"Clin Immunol"},{"issue":"8","key":"2305_CR26","first-page":"1504","volume":"24","author":"M Jongen-Lavrencic","year":"1997","unstructured":"Jongen-Lavrencic M, Peeters HR, Wognum A, Vreugdenhil G, Breedveld FC, Swaak AJ. Elevated levels of inflammatory cytokines in bone marrow of patients with rheumatoid arthritis and anemia of chronic disease. J Rheumatol. 1997;24(8):1504\u20139.","journal-title":"J Rheumatol"},{"issue":"5","key":"2305_CR27","first-page":"830","volume":"21","author":"M Tanabe","year":"1994","unstructured":"Tanabe M, Ochi T, Tomita T, Suzuki R, Sakata T, Shimaoka Y, et al. Remarkable elevation of interleukin 6 and interleukin 8 levels in the bone marrow serum of patients with rheumatoid arthritis. J Rheumatol. 1994;21(5):830\u20135.","journal-title":"J Rheumatol"},{"issue":"2\u20133","key":"2305_CR28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.bcmd.2013.09.004","volume":"52","author":"BJ McCranor","year":"2014","unstructured":"McCranor BJ, Kim MJ, Cruz NM, Xue QL, Berger AE, Walston JD, et al. Interleukin-6 directly impairs the erythroid development of human TF-1 erythroleukemic cells. Blood Cells Mol Dis. 2014;52(2\u20133):126\u201333. doi: 10.1016\/j.bcmd.2013.09.004 .","journal-title":"Blood Cells Mol Dis"},{"issue":"11","key":"2305_CR29","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-07-4153","volume":"14","author":"S Sharma","year":"2008","unstructured":"Sharma S, Nemeth E, Chen YH, Goodnough J, Huston A, Roodman GD, et al. Involvement of hepcidin in the anemia of multiple myeloma. Clin Cancer Res. 2008;14(11):3262\u20137. doi: 10.1158\/1078-0432.ccr-07-4153 .","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2305_CR30","doi-asserted-by":"crossref","first-page":"e93283","DOI":"10.1371\/journal.pone.0093283","volume":"9","author":"A Kim","year":"2014","unstructured":"Kim A, Rivera S, Shprung D, Limbrick D, Gabayan V, Nemeth E, et al. Mouse models of anemia of cancer. PLoS One. 2014;9(3):e93283. doi: 10.1371\/journal.pone.0093283 .","journal-title":"PLoS One"},{"issue":"6","key":"2305_CR31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.33549\/physiolres.930841","volume":"55","author":"M Vokurka","year":"2006","unstructured":"Vokurka M, Krijt J, Sulc K, Necas E. Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res. 2006;55(6):667\u201374.","journal-title":"Physiol Res"},{"issue":"1","key":"2305_CR32","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1182\/blood.V83.1.260.260","volume":"83","author":"I Graziadei","year":"1994","unstructured":"Graziadei I, Gaggl S, Kaserbacher R, Braunsteiner H, Vogel W. The acute-phase protein alpha 1-antitrypsin inhibits growth and proliferation of human early erythroid progenitor cells (burst-forming units-erythroid) and of human erythroleukemic cells (K562) in vitro by interfering with transferrin iron uptake. Blood. 1994;83(1):260\u20138.","journal-title":"Blood"},{"issue":"10","key":"2305_CR33","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1182\/blood.V99.10.3505","volume":"99","author":"FM Torti","year":"2002","unstructured":"Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood. 2002;99(10):3505\u201316.","journal-title":"Blood"},{"issue":"7","key":"2305_CR34","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3899\/jrheum.121389","volume":"40","author":"K Shimamoto","year":"2013","unstructured":"Shimamoto K, Ito T, Ozaki Y, Amuro H, Tanaka A, Nishizawa T, et al. Serum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritis. J Rheumatol. 2013;40(7):1074\u201381. doi: 10.3899\/jrheum.121389 .","journal-title":"J Rheumatol"},{"issue":"10","key":"2305_CR35","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1182\/blood-2008-05-155846","volume":"112","author":"N Nishimoto","year":"2008","unstructured":"Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959\u201364. doi: 10.1182\/blood-2008-05-155846 .","journal-title":"Blood"},{"issue":"10","key":"2305_CR36","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1373\/49.10.1573","volume":"49","author":"C Brugnara","year":"2003","unstructured":"Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 2003;49(10):1573\u20138.","journal-title":"Clin Chem"},{"issue":"4","key":"2305_CR37","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood.V81.4.956.956","volume":"81","author":"C Brugnara","year":"1993","unstructured":"Brugnara C, Chambers LA, Malynn E, Goldberg MA, Kruskall MS. Red blood cell regeneration induced by subcutaneous recombinant erythropoietin: iron-deficient erythropoiesis in iron-replete subjects. Blood. 1993;81(4):956\u201364.","journal-title":"Blood"},{"issue":"1","key":"2305_CR38","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.smim.2014.01.007","volume":"26","author":"Q Chang","year":"2014","unstructured":"Chang Q, Daly L, Bromberg J. The IL-6 feed-forward loop: a driver of tumorigenesis. Semin Immunol. 2014;26(1):48\u201353. doi: 10.1016\/j.smim.2014.01.007 .","journal-title":"Semin Immunol"},{"issue":"12","key":"2305_CR39","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1002\/pro.5560031213","volume":"3","author":"A Hammacher","year":"1994","unstructured":"Hammacher A, Ward LD, Weinstock J, Treutlein H, Yasukawa K, Simpson RJ. Structure-function analysis of human IL-6: identification of two distinct regions that are important for receptor binding. Protein Sci. 1994;3(12):2280\u201393. doi: 10.1002\/pro.5560031213 .","journal-title":"Protein Sci"},{"issue":"1","key":"2305_CR40","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.smim.2014.01.009","volume":"26","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Ogata A, Kishimoto T. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy. Semin Immunol. 2014;26(1):88\u201396. doi: 10.1016\/j.smim.2014.01.009 .","journal-title":"Semin Immunol"},{"issue":"10","key":"2305_CR41","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1093\/annonc\/mdv309","volume":"26","author":"EM Dijkgraaf","year":"2015","unstructured":"Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, et al. A phase I trial combining carboplatin\/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-alpha2b in patients with recurrent epithelial ovarian cancer. Ann Oncol. 2015;26(10):2141\u20139. doi: 10.1093\/annonc\/mdv309 .","journal-title":"Ann Oncol"},{"issue":"6","key":"2305_CR42","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2012.44.2020","volume":"31","author":"K Ando","year":"2013","unstructured":"Ando K, Takahashi F, Motojima S, Nakashima K, Kaneko N, Hoshi K, et al. Possible role for tocilizumab, an anti-interleukin-6 receptor antibody, in treating cancer cachexia. J Clin Oncol. 2013;31(6):e69\u201372. doi: 10.1200\/jco.2012.44.2020 .","journal-title":"J Clin Oncol"},{"issue":"2","key":"2305_CR43","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1016\/j.jpainsymman.2013.01.009","volume":"46","author":"H Hirata","year":"2013","unstructured":"Hirata H, Tetsumoto S, Kijima T, Kida H, Kumagai T, Takahashi R, et al. Favorable responses to tocilizumab in two patients with cancer-related cachexia. J Pain Symptom Manage. 2013;46(2):e9\u201313. doi: 10.1016\/j.jpainsymman.2013.01.009 .","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"2305_CR44","doi-asserted-by":"crossref","first-page":"e102436","DOI":"10.1371\/journal.pone.0102436","volume":"9","author":"K Ando","year":"2014","unstructured":"Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, et al. Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. PLoS One. 2014;9(7):e102436. doi: 10.1371\/journal.pone.0102436 .","journal-title":"PLoS One"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-2305-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T20:35:08Z","timestamp":1655498108000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-2305-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,11]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2305"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-2305-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,11]]},"article-number":"270"}}